hydroxyurea has been researched along with Leg Ulcer in 96 studies
Leg Ulcer: Ulceration of the skin and underlying structures of the lower extremity. About 90% of the cases are due to venous insufficiency (VARICOSE ULCER), 5% to arterial disease, and the remaining 5% to other causes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The use of hydroxyurea for the prevention of sickle cell crises in patients with homozygous HbS disease is now well established." | 9.09 | Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. ( Kalotychou, V; Loukopoulos, D; Loutradi, A; Schina, M; Theodoropoulos, I; Voskaridou, E, 2000) |
| "Hydroxyurea (HU) is effective in controlling thrombocytosis while reducing the risk of thrombosis in essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF)." | 8.83 | Leg ulcers in elderly on hydroxyurea: a single center experience in Ph- myeloproliferative disorders and review of literature. ( Fabris, F; Luzzatto, G; Randi, ML; Ruzzon, E; Scandellari, R; Tezza, F, 2006) |
| "Hydroxyurea is an antineoplastic agent commonly used to treat myeloproliferative disorders and other nonneoplastic conditions." | 8.80 | Hydroxyurea-induced leg ulceration in 14 patients. ( Best, PJ; Daoud, MS; Petitt, RM; Pittelkow, MR, 1998) |
| "This report evaluates the use of timolol in 2 patients with long-term hydroxyurea use and lower-extremity ulcers resistant to other treatments." | 8.31 | Treatment of Hydroxyurea-Induced Ulcers With Timolol. ( Hoss, E; Hwang, AS; Pittelkow, MR; Yang, YW, 2023) |
| " Hydroxyurea-induced leg ulcer has been found in patients on long-term hydroxyurea therapy." | 8.02 | Chronic Myeloid Leukaemia with Sudden Bilateral Deafness and Leg Ulcer Associated with Hydroxyurea Therapy. ( Ibiam, FA; Nnachi, OA; Okoh, NU; Okoye, AE; Ugwu, CN; Ugwu, GC; Ugwu, NI, 2021) |
| "Hydroxyurea is a chemotherapeutic agent used for myeloproliferative disorders and sickle cell anemia that is well known to cause painful mucocutaneous ulcers, typically involving the legs or mouth." | 8.02 | Hydroxyurea-induced genital ulcers and erosions: Two case reports. ( Blum, AE; Kemp, JM; Tsiaras, WG, 2021) |
| "Hydroxyurea (HU) resistance or intolerance occurs in 15 to 24% of patients with polycythemia vera (PV)." | 7.91 | Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis. ( Delforge, M; Demuynck, T; Devos, T; Vandenberghe, P; Verhoef, G, 2019) |
| "A 70-year-old woman is treated with hydroxyurea for polycythemia vera." | 7.77 | [Hydroxyurea induced-leg ulcer in polycythemia vera]. ( Aissaoui, L; El Guellali, N; Ezzine, N; Fazaa, B; Kamoun, MR; Khaled, A; Robbana, F, 2011) |
| "A 68-year-old women with polycythemia vera was treated with hydroxyurea for 8 years and developed painful ulcers on her lower legs, multiple hypertrophic actinic keratoses and a squamous cell carcinoma." | 7.75 | [Cutaneous side effects of hydroxyurea treatment for polycythemia vera]. ( Akanay-Diesel, S; Hanneken, S; Hoff, NP; Pippirs, U; Schulte, KW, 2009) |
| "The onset of a dermatomyositis-like rash and persistent skin ulcers during long-term treatment with hydroxyurea is a very rare event that has not been fully described in the literature." | 7.75 | [Multiple, painful, treatment-resistant leg ulcers associated with dermatomyositis-like lesions over the interphalangeal joints induced by hydroxyurea]. ( Guillén-Barona, C; Martorell-Calatayud, A; Nagore-Enguídanos, E; Requena, C, 2009) |
| "The development of painful leg ulcers in the ankle area is a rare and only partially described complication in patients receiving high-dose, long-term hydroxyurea treatment for myeloproliferative diseases." | 7.74 | Hydroxyurea-induced leg ulcers treated with a protease-modulating matrix. ( Dini, V; Romanelli, M; Romanelli, P, 2007) |
| "We report a preliminary clinical experience in the use of hydroxyurea (HU) for the treatment of leg ulcers in thalassaemia intermedia patients with associated endocrine complications." | 7.72 | Healing of leg ulcers with hydroxyurea in thalassaemia intermedia patients with associated endocrine complications. ( De Sanctis, V; Fortini, M; Gamberini, MR, 2004) |
| "We report the case of an immunosuppressed patient who developed a hydroxyurea-induced leg ulcer with subclinical MRSA infection which was subsequently treated with topical application of manuka honey, without cessation of hydroxyurea or cyclosporin." | 7.71 | Healing of an MRSA-colonized, hydroxyurea-induced leg ulcer with honey. ( Cooper, RA; Grey, J; Harding, KG; Natarajan, S; Williamson, D, 2001) |
| "A 51-year-old male who had intractable leg ulcers during treatment for chronic myelogenous leukaemia with hydroxyurea (HU) is reported." | 7.71 | Successful treatment for leg ulcers due to hydroxyurea in a patient with chronic myelogenous leukaemia. ( Kamada, T; Kawabata, H; Makino, T; Suzuki, S; Takatsuka, Y; Takeuchi, S; Utsunomiya, A, 2002) |
| "Hydroxyurea (HU) is usually a well-tolerated antineoplastic agent, which is commonly used in the treatment of myeloproliferative disorders." | 7.71 | [Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders]. ( Olesen, LH; Pedersen, BB, 2001) |
| "The association of lower leg ulcer development and hydroxyurea therapy in patients with myeloproliferative disorders has been reported previously." | 7.71 | Aggressive, extensive, vasculitic leg ulceration associated with hydroxyurea therapy and a fatal outcome. ( Kirby, B; Stewart, EJ; Young, HS, 2001) |
| "We report the case of an elderly woman who had been on hydroxyurea for long-standing widespread psoriasis." | 7.70 | Dermatomyositis-like eruption and leg ulceration caused by hydroxyurea in a patient with psoriasis. ( Lanigan, SW; Varma, S, 1999) |
| "This longest-reported series of patients confirms the role of hydroxyurea therapy in the onset of leg ulcerations." | 7.70 | Leg ulcers and hydroxyurea: forty-one cases. ( Baudot, N; Beylot, C; Bonnetblanc, JM; Dandurand, M; Debure, C; Denoeux, JP; Dubertret, L; Frances, C; Gauthier, O; Guillot, B; Humbert, P; Lambert, D; Lok, C; Lorette, G; Loubeyres, S; Morel, P; Roux, ME; Sirieix, ME; Vaillant, L, 1999) |
| "We report four cases of cutaneous lower leg ulcers associated with hydroxyurea treatment for myeloproliferative disorders." | 7.68 | Hydroxyurea and lower leg ulcers. ( Margolis, DJ; Nguyen, TV, 1993) |
| " Growing considerations for this population in the literature include cutaneous reactions to common treatments such as hydroxyurea and clinical management of the intersection between sickle cell disease and conditions like plaque psoriasis." | 5.41 | Cutaneous manifestations of sickle cell disease: an updated review. ( Dick, A; Khachemoune, A; Schwartzman, G, 2023) |
| "Hydroxyurea (HU) is an antineoplastic drug used in the treatment of chronic myeloproliferative neoplasms (MPNs)." | 5.40 | Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma. ( Antar, A; El-Majzoub, N; Ghosn, S; Ishak, RS; Mahfouz, R; Otrock, ZK; Taher, AT, 2014) |
| "Hydroxyurea (HU) is a cytotoxic agent, which leads to inactivation of ribonucleotide reductase, inhibition of cellular DNA synthesis, and cell death in the S phase." | 5.34 | Hydroxyurea associated leg ulcer succesfully treated with hyperbaric oxygen in a diabetic patient. ( Akinci, B; Atabey, A; Ilgezdi, S; Yesil, S, 2007) |
| "We decided to treat the leg ulcers following a modern phase-adapted wound-healing strategy and continued hydroxyurea therapy until complete healing of the ulcers." | 5.33 | Leg ulcer in a patient associated with hydroxyurea therapy. ( Dissemond, J; Franckson, T; Goos, M; Hoeft, D; Knab, J; Kroger, K, 2006) |
| "Hydroxyurea is an antineoplasic agent usually used in myeloproliferative syndromes, but also in other benign pathological circumstances." | 5.33 | [Leg ulcer due to hydroxyurea. A case report]. ( Debonne, JM; Diagne-Guèye, NM; Fall, F; Gning, SB; Mbaye, PS; Ndiaye, B, 2006) |
| " The dosage of HU was decreased to 500 mg daily when the platelet counts were found to be within normal levels." | 5.31 | Leg ulcers and hydroxyurea: report of three cases with essential thrombocythemia. ( Adigüzel, C; Cömert, A; Demirçay, Z, 2002) |
| "The occurrence of leg ulcers have been described in 8." | 5.30 | Hydroxyurea-induced leg ulcers: is macroerythrocytosis a pathogenic factor? ( García-Aranda, JM; Moreno, JC; Vélez, A, 1999) |
| "We report a 45-year-old male with chronic myelogenous leukemia (CML) who experienced skin ulcers of the left lateral malleolus and dorsum of both feet." | 5.30 | [Bilateral leg ulcers with pathologic evidence of small vessel vasculitis by skin biopsy during hydroxyurea therapy of chronic myelogenous leukemia]. ( Irimajiri, J; Ito, T; Kanazawa, A; Kawahara, Y; Kudo, H; Ohkubo, H; Tomiyama, J; Uchino, S; Yano, K, 1997) |
| "The use of hydroxyurea for the prevention of sickle cell crises in patients with homozygous HbS disease is now well established." | 5.09 | Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. ( Kalotychou, V; Loukopoulos, D; Loutradi, A; Schina, M; Theodoropoulos, I; Voskaridou, E, 2000) |
| "An electronic search encompassing MEDLINE, PubMed, Cochrane Library, and Scopus was completed using the following search terms: rheumatoid arthritis; systemic sclerosis; systemic lupus erythematosus; antineutrophil cytoplasmic antibody-associated vasculitis; mixed connective tissue disease; antiphospholipid syndrome; pyoderma gangrenosum; thromboangiitis obliterans; cryoglobulinemia; hydroxyurea; sickle cell; atrophie blanche; livedoid vasculitis; cholesterol emboli; calciphylaxis; antiphospholipid antibodies; prothrombotic; combined with the terms: chronic wound and leg ulcer." | 4.95 | Vasculitic and autoimmune wounds. ( Angra, D; McNish, S; Rahimi, H; Shanmugam, VK, 2017) |
| "Hydroxyurea (HU) is effective in controlling thrombocytosis while reducing the risk of thrombosis in essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF)." | 4.83 | Leg ulcers in elderly on hydroxyurea: a single center experience in Ph- myeloproliferative disorders and review of literature. ( Fabris, F; Luzzatto, G; Randi, ML; Ruzzon, E; Scandellari, R; Tezza, F, 2006) |
| "Hydroxyurea is an antineoplastic agent commonly used to treat myeloproliferative disorders and other nonneoplastic conditions." | 4.80 | Hydroxyurea-induced leg ulceration in 14 patients. ( Best, PJ; Daoud, MS; Petitt, RM; Pittelkow, MR, 1998) |
| "Leg ulcers are a relatively frequent problem in patients with myeloproliferative disorders under treatment with hydroxyurea (HU)." | 4.80 | Leg ulcers in patients with myeloproliferative disorders: disease- or treatment-related? ( Bader, U; Banyai, M; Böni, R; Burg, G; Hafner, J, 2000) |
| "This report evaluates the use of timolol in 2 patients with long-term hydroxyurea use and lower-extremity ulcers resistant to other treatments." | 4.31 | Treatment of Hydroxyurea-Induced Ulcers With Timolol. ( Hoss, E; Hwang, AS; Pittelkow, MR; Yang, YW, 2023) |
| " Hydroxyurea-induced leg ulcer has been found in patients on long-term hydroxyurea therapy." | 4.02 | Chronic Myeloid Leukaemia with Sudden Bilateral Deafness and Leg Ulcer Associated with Hydroxyurea Therapy. ( Ibiam, FA; Nnachi, OA; Okoh, NU; Okoye, AE; Ugwu, CN; Ugwu, GC; Ugwu, NI, 2021) |
| "Hydroxyurea is a chemotherapeutic agent used for myeloproliferative disorders and sickle cell anemia that is well known to cause painful mucocutaneous ulcers, typically involving the legs or mouth." | 4.02 | Hydroxyurea-induced genital ulcers and erosions: Two case reports. ( Blum, AE; Kemp, JM; Tsiaras, WG, 2021) |
| "Hydroxyurea (HU) resistance or intolerance occurs in 15 to 24% of patients with polycythemia vera (PV)." | 3.91 | Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis. ( Delforge, M; Demuynck, T; Devos, T; Vandenberghe, P; Verhoef, G, 2019) |
| "Hydroxyurea (HU) has been shown to induce a variety of cutaneous adverse reactions, including severe leg ulcers." | 3.78 | A multidisciplinary team approach to hydroxyurea-associated chronic wound with squamous cell carcinoma. ( Berger, A; Blumberg, S; Chen, W; McMeeking, A; O'Neill, D; Pastar, I; Ross, F; Stone, T, 2012) |
| "A 70-year-old woman is treated with hydroxyurea for polycythemia vera." | 3.77 | [Hydroxyurea induced-leg ulcer in polycythemia vera]. ( Aissaoui, L; El Guellali, N; Ezzine, N; Fazaa, B; Kamoun, MR; Khaled, A; Robbana, F, 2011) |
| "A 68-year-old women with polycythemia vera was treated with hydroxyurea for 8 years and developed painful ulcers on her lower legs, multiple hypertrophic actinic keratoses and a squamous cell carcinoma." | 3.75 | [Cutaneous side effects of hydroxyurea treatment for polycythemia vera]. ( Akanay-Diesel, S; Hanneken, S; Hoff, NP; Pippirs, U; Schulte, KW, 2009) |
| "The onset of a dermatomyositis-like rash and persistent skin ulcers during long-term treatment with hydroxyurea is a very rare event that has not been fully described in the literature." | 3.75 | [Multiple, painful, treatment-resistant leg ulcers associated with dermatomyositis-like lesions over the interphalangeal joints induced by hydroxyurea]. ( Guillén-Barona, C; Martorell-Calatayud, A; Nagore-Enguídanos, E; Requena, C, 2009) |
| "The development of painful leg ulcers in the ankle area is a rare and only partially described complication in patients receiving high-dose, long-term hydroxyurea treatment for myeloproliferative diseases." | 3.74 | Hydroxyurea-induced leg ulcers treated with a protease-modulating matrix. ( Dini, V; Romanelli, M; Romanelli, P, 2007) |
| "We report a preliminary clinical experience in the use of hydroxyurea (HU) for the treatment of leg ulcers in thalassaemia intermedia patients with associated endocrine complications." | 3.72 | Healing of leg ulcers with hydroxyurea in thalassaemia intermedia patients with associated endocrine complications. ( De Sanctis, V; Fortini, M; Gamberini, MR, 2004) |
| "We report the case of an immunosuppressed patient who developed a hydroxyurea-induced leg ulcer with subclinical MRSA infection which was subsequently treated with topical application of manuka honey, without cessation of hydroxyurea or cyclosporin." | 3.71 | Healing of an MRSA-colonized, hydroxyurea-induced leg ulcer with honey. ( Cooper, RA; Grey, J; Harding, KG; Natarajan, S; Williamson, D, 2001) |
| "Our rate of hydroxyurea-induced leg ulcers (29%) is higher than that reported for patients with myeloproliferative syndromes (9%)." | 3.71 | Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. ( Aractingi, S; Chaine, B; Girot, R; Neonato, MG, 2001) |
| "A 51-year-old male who had intractable leg ulcers during treatment for chronic myelogenous leukaemia with hydroxyurea (HU) is reported." | 3.71 | Successful treatment for leg ulcers due to hydroxyurea in a patient with chronic myelogenous leukaemia. ( Kamada, T; Kawabata, H; Makino, T; Suzuki, S; Takatsuka, Y; Takeuchi, S; Utsunomiya, A, 2002) |
| "Hydroxyurea (HU) is usually a well-tolerated antineoplastic agent, which is commonly used in the treatment of myeloproliferative disorders." | 3.71 | [Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders]. ( Olesen, LH; Pedersen, BB, 2001) |
| "The association of lower leg ulcer development and hydroxyurea therapy in patients with myeloproliferative disorders has been reported previously." | 3.71 | Aggressive, extensive, vasculitic leg ulceration associated with hydroxyurea therapy and a fatal outcome. ( Kirby, B; Stewart, EJ; Young, HS, 2001) |
| "Hydroxyurea was stopped for medical reasons in 11 patients: 6 failures, 1 pregnancy, 1 cutaneous rash, 1 leg ulcer, 1 lupus." | 3.70 | Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease. ( Bachir, D; Bégué, P; Bernaudin, F; de Montalembert, M; Micheau, M; Thuret, I, 1999) |
| "We report the case of an elderly woman who had been on hydroxyurea for long-standing widespread psoriasis." | 3.70 | Dermatomyositis-like eruption and leg ulceration caused by hydroxyurea in a patient with psoriasis. ( Lanigan, SW; Varma, S, 1999) |
| "This longest-reported series of patients confirms the role of hydroxyurea therapy in the onset of leg ulcerations." | 3.70 | Leg ulcers and hydroxyurea: forty-one cases. ( Baudot, N; Beylot, C; Bonnetblanc, JM; Dandurand, M; Debure, C; Denoeux, JP; Dubertret, L; Frances, C; Gauthier, O; Guillot, B; Humbert, P; Lambert, D; Lok, C; Lorette, G; Loubeyres, S; Morel, P; Roux, ME; Sirieix, ME; Vaillant, L, 1999) |
| "We report four cases of cutaneous lower leg ulcers associated with hydroxyurea treatment for myeloproliferative disorders." | 3.68 | Hydroxyurea and lower leg ulcers. ( Margolis, DJ; Nguyen, TV, 1993) |
| " Accordingly, we conclude that clinical trials in SCD designed to increase the bioavailability of NO or association studies in which SCD clinical manifestations are related to plasma hemoglobin via its surrogates should be viewed with caution." | 2.46 | Pulmonary hypertension and nitric oxide depletion in sickle cell disease. ( Bunn, HF; Dover, GJ; Hebbel, RP; Nathan, DG; Platt, OS; Rosse, WF; Ware, RE, 2010) |
| "Hydroxyurea has demonstrated efficacy in adults with sickle cell disease." | 2.44 | Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. ( Bass, EB; Beach, MC; Haywood, C; Lanzkron, S; Park, H; Segal, JB; Strouse, JJ; Wilson, R; Witkop, C, 2008) |
| "The lower legs of homozygous sickle cell anemia patients are areas of marginal vascularity where minor abrasions become foci of inflammation." | 2.40 | [Falciform anemia and Plasmodium falciparum malaria: a threat to flap survival?]. ( Humbert, J; Loutan, L; Mariéthoz, S; Montandon, D; Pittet, B, 1999) |
| "This study showed that skin carcinogenesis did not occur in our series of SCD patients exposed to transforming events such as long term HU treatment or prolonged leg ulcers." | 1.56 | Sickle cell disease induces resistance to cutaneous carcinogenesis. ( Aractingi, S; Habibi, A; Lionnet, F; Senet, P; Soutou, B, 2020) |
| "Hydroxyurea (HU) is an antineoplastic drug used in chronic myeloproliferative disorders." | 1.43 | [MALLEOLAR ULCERS ASSOCIATED TO HYDROXYUREA TREATMENT]. ( Aparicio Julián, MA; Masa Font, R; Mayorga Baca, MS; Morató García, C; Sánchez Schmidt, JM, 2016) |
| "Hydroxyurea (HU) is an antineoplastic drug used in the treatment of chronic myeloproliferative neoplasms (MPNs)." | 1.40 | Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma. ( Antar, A; El-Majzoub, N; Ghosn, S; Ishak, RS; Mahfouz, R; Otrock, ZK; Taher, AT, 2014) |
| "Sickle cell disease is a genetic disorder of hemoglobin synthesis leading to a deformation of the red blood cell." | 1.38 | Sickle cell disease and leg ulcers. ( Alavi, A; Bazakas, A; Ladizinski, B; Mistry, N; Salcido, R; Sibbald, RG, 2012) |
| "Leg ulcers are a frequent and serious complication of polycythemia vera (PV)." | 1.36 | [Leg ulcers in patient affected by polycythemia vera in treatment with hydroxycarbamide. Case report]. ( Alfano, C; Arleo, S; Chiummariello, S, 2010) |
| "Hydroxyurea (HU) is a cytotoxic agent, which leads to inactivation of ribonucleotide reductase, inhibition of cellular DNA synthesis, and cell death in the S phase." | 1.34 | Hydroxyurea associated leg ulcer succesfully treated with hyperbaric oxygen in a diabetic patient. ( Akinci, B; Atabey, A; Ilgezdi, S; Yesil, S, 2007) |
| "We decided to treat the leg ulcers following a modern phase-adapted wound-healing strategy and continued hydroxyurea therapy until complete healing of the ulcers." | 1.33 | Leg ulcer in a patient associated with hydroxyurea therapy. ( Dissemond, J; Franckson, T; Goos, M; Hoeft, D; Knab, J; Kroger, K, 2006) |
| "Hydroxyurea is an antineoplasic agent usually used in myeloproliferative syndromes, but also in other benign pathological circumstances." | 1.33 | [Leg ulcer due to hydroxyurea. A case report]. ( Debonne, JM; Diagne-Guèye, NM; Fall, F; Gning, SB; Mbaye, PS; Ndiaye, B, 2006) |
| "The first case was a chronic myeloid leukemia (CML) patient on HU 1." | 1.33 | Hydroxyurea induced perimalleolar ulcers. ( Lakshmi, N; Saravu, K; Shastry, BA; Thomas, J; Velappan, P, 2006) |
| " This is an adverse effect of hydroxyurea that is not infrequently seen but is difficult to recognise." | 1.32 | [Ulcers on the legs and feet: a seldom recognised side effect of hydroxyurea]. ( Janssen, JJ; Ossenkoppele, GJ, 2003) |
| "Hydroxyurea is a treatment of myeloproliferative syndromes." | 1.31 | [Secondary cutaneous effects of hydroxyurea: prospective study of 26 patients from a dermatologic consultation]. ( Bernard, P; Leborgne, G; Potron, G; Salmon-Ehr, V; Vilque, JP, 2000) |
| " The dosage of HU was decreased to 500 mg daily when the platelet counts were found to be within normal levels." | 1.31 | Leg ulcers and hydroxyurea: report of three cases with essential thrombocythemia. ( Adigüzel, C; Cömert, A; Demirçay, Z, 2002) |
| "The occurrence of leg ulcers have been described in 8." | 1.30 | Hydroxyurea-induced leg ulcers: is macroerythrocytosis a pathogenic factor? ( García-Aranda, JM; Moreno, JC; Vélez, A, 1999) |
| "We report a 45-year-old male with chronic myelogenous leukemia (CML) who experienced skin ulcers of the left lateral malleolus and dorsum of both feet." | 1.30 | [Bilateral leg ulcers with pathologic evidence of small vessel vasculitis by skin biopsy during hydroxyurea therapy of chronic myelogenous leukemia]. ( Irimajiri, J; Ito, T; Kanazawa, A; Kawahara, Y; Kudo, H; Ohkubo, H; Tomiyama, J; Uchino, S; Yano, K, 1997) |
| "A distinct cutaneous reaction to long-term administration of hydroxyurea has been characterized." | 1.30 | Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea. ( Daoud, MS; Gibson, LE; Pittelkow, MR, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 21 (21.88) | 18.2507 |
| 2000's | 41 (42.71) | 29.6817 |
| 2010's | 27 (28.13) | 24.3611 |
| 2020's | 7 (7.29) | 2.80 |
| Authors | Studies |
|---|---|
| Tolu, SS | 1 |
| Crouch, A | 1 |
| Choi, J | 1 |
| Gao, Q | 1 |
| Reyes-Gil, M | 1 |
| Ogu, UO | 1 |
| Vinces, G | 1 |
| Minniti, CP | 2 |
| Dick, A | 3 |
| Schwartzman, G | 3 |
| Khachemoune, A | 4 |
| Hwang, AS | 1 |
| Hoss, E | 1 |
| Pittelkow, MR | 3 |
| Yang, YW | 1 |
| Soutou, B | 1 |
| Senet, P | 1 |
| Lionnet, F | 2 |
| Habibi, A | 2 |
| Aractingi, S | 2 |
| Bulte, CA | 1 |
| Hoegler, KM | 1 |
| Kutlu, Ö | 1 |
| Ugwu, NI | 1 |
| Okoye, AE | 1 |
| Ugwu, CN | 1 |
| Ibiam, FA | 1 |
| Nnachi, OA | 1 |
| Ugwu, GC | 1 |
| Okoh, NU | 1 |
| Blum, AE | 1 |
| Tsiaras, WG | 1 |
| Kemp, JM | 1 |
| Platto, J | 1 |
| Alexander, CE | 1 |
| Kurtzman, DJB | 1 |
| Soya, E | 1 |
| Makowski, C | 1 |
| Blaise, S | 1 |
| Demuynck, T | 1 |
| Verhoef, G | 1 |
| Delforge, M | 1 |
| Vandenberghe, P | 1 |
| Devos, T | 1 |
| Crittenden, SC | 1 |
| Gilbert, JE | 1 |
| Callen, JP | 1 |
| de Unamuno-Bustos, B | 1 |
| Ballester-Sánchez, R | 1 |
| Sabater Marco, V | 1 |
| Vilata-Corell, JJ | 1 |
| Lopes, FC | 1 |
| Ferreira, R | 1 |
| Albuquerque, DM | 1 |
| Silveira, AA | 1 |
| Costa, R | 1 |
| Soares, R | 1 |
| Costa, FF | 1 |
| Conran, N | 1 |
| Antar, A | 1 |
| Ishak, RS | 1 |
| Otrock, ZK | 1 |
| El-Majzoub, N | 1 |
| Ghosn, S | 1 |
| Mahfouz, R | 1 |
| Taher, AT | 1 |
| Belini Junior, E | 1 |
| Silva, DG | 1 |
| Torres, Lde S | 1 |
| Okumura, JV | 1 |
| Lobo, CL | 1 |
| Bonini-Domingos, CR | 1 |
| Kato, GJ | 2 |
| Pollack, S | 1 |
| Aparicio Julián, MA | 1 |
| Mayorga Baca, MS | 1 |
| Morató García, C | 1 |
| Masa Font, R | 1 |
| Sánchez Schmidt, JM | 1 |
| Koch, L | 1 |
| Lichem, R | 1 |
| Cerroni, L | 1 |
| Aberer, W | 1 |
| Massone, C | 1 |
| Bueno-Rodríguez, A | 1 |
| Aguayo-Carreras, P | 1 |
| Martínez-López, A | 1 |
| Pérez-López, I | 1 |
| Ruiz-Villaverde, R | 1 |
| Shanmugam, VK | 1 |
| Angra, D | 1 |
| Rahimi, H | 1 |
| McNish, S | 1 |
| Dissemond, J | 4 |
| Körber, A | 2 |
| Hoff, NP | 1 |
| Akanay-Diesel, S | 1 |
| Pippirs, U | 1 |
| Schulte, KW | 1 |
| Hanneken, S | 1 |
| Martorell-Calatayud, A | 1 |
| Requena, C | 1 |
| Nagore-Enguídanos, E | 1 |
| Guillén-Barona, C | 1 |
| Bunn, HF | 1 |
| Nathan, DG | 1 |
| Dover, GJ | 1 |
| Hebbel, RP | 1 |
| Platt, OS | 1 |
| Rosse, WF | 1 |
| Ware, RE | 1 |
| Chiummariello, S | 1 |
| Arleo, S | 1 |
| Alfano, C | 1 |
| Martínez-Trillos, A | 1 |
| Gaya, A | 1 |
| Maffioli, M | 1 |
| Arellano-Rodrigo, E | 1 |
| Calvo, X | 1 |
| Díaz-Beyá, M | 1 |
| Cervantes, F | 1 |
| Nzouakou, R | 1 |
| Bachir, D | 2 |
| Lavaud, A | 1 |
| Lee, K | 1 |
| Hulin, A | 1 |
| Jouault, H | 1 |
| Préhu, C | 1 |
| Roudot-Thoraval, F | 1 |
| Girot, R | 2 |
| Galactéros, F | 1 |
| Kikuchi, K | 1 |
| Arita, K | 1 |
| Tateishi, Y | 1 |
| Onozawa, M | 1 |
| Akiyama, M | 1 |
| Shimizu, H | 1 |
| Khaled, A | 1 |
| El Guellali, N | 1 |
| Aissaoui, L | 1 |
| Robbana, F | 1 |
| Ezzine, N | 1 |
| Fazaa, B | 1 |
| Kamoun, MR | 1 |
| Goerge, T | 1 |
| Schellong, G | 1 |
| Mesters, RM | 1 |
| Berdel, WE | 1 |
| Gonçalves, RP | 1 |
| Elias, DB | 1 |
| Magalhães, HI | 1 |
| de Souza, JH | 1 |
| Stone, T | 1 |
| Berger, A | 1 |
| Blumberg, S | 1 |
| O'Neill, D | 1 |
| Ross, F | 1 |
| McMeeking, A | 1 |
| Chen, W | 1 |
| Pastar, I | 1 |
| Francis, S | 1 |
| Bareford, D | 1 |
| Baggott, C | 1 |
| Baginott, C | 1 |
| Thachil, J | 1 |
| Novelli, EM | 1 |
| Ragni, MV | 1 |
| Zhang, Y | 1 |
| Hildesheim, ME | 1 |
| Nouraie, M | 1 |
| Barge, S | 1 |
| Meyer, MP | 1 |
| Hassett, AC | 1 |
| Gordeuk, VR | 1 |
| Gladwin, MT | 1 |
| Isenberg, JS | 1 |
| Ladizinski, B | 1 |
| Bazakas, A | 1 |
| Mistry, N | 1 |
| Alavi, A | 1 |
| Sibbald, RG | 1 |
| Salcido, R | 1 |
| Natarajan, S | 1 |
| Williamson, D | 1 |
| Grey, J | 1 |
| Harding, KG | 1 |
| Cooper, RA | 1 |
| Demirçay, Z | 1 |
| Cömert, A | 1 |
| Adigüzel, C | 1 |
| Sastre, JL | 1 |
| Bravo, A | 1 |
| Tembrás, S | 2 |
| Gómez, R | 2 |
| Ulibarrena, C | 2 |
| Janssen, JJ | 1 |
| Ossenkoppele, GJ | 1 |
| Bravo Blanco, AM | 1 |
| Moral, JL | 1 |
| Obdulia Vazquez, M | 1 |
| Tripathi, AK | 1 |
| Ahmad, R | 1 |
| Sawlani, KK | 1 |
| Welt, K | 1 |
| Ott, S | 1 |
| Weiss, JM | 1 |
| Scharffetter-Kochanek, K | 1 |
| Trent, JT | 1 |
| Kirsner, RS | 2 |
| Hoeft, D | 1 |
| Knab, J | 1 |
| Franckson, T | 1 |
| Kroger, K | 1 |
| Goos, M | 1 |
| Gamberini, MR | 1 |
| Fortini, M | 1 |
| De Sanctis, V | 1 |
| Saravu, K | 1 |
| Velappan, P | 1 |
| Lakshmi, N | 1 |
| Shastry, BA | 1 |
| Thomas, J | 1 |
| Ruzzon, E | 1 |
| Randi, ML | 1 |
| Tezza, F | 1 |
| Luzzatto, G | 1 |
| Scandellari, R | 1 |
| Fabris, F | 1 |
| Zaccaria, E | 1 |
| Cozzani, E | 1 |
| Parodi, A | 1 |
| Haniffa, MA | 1 |
| Speight, EL | 1 |
| Rappoport, L | 1 |
| Grabbe, S | 1 |
| Akinci, B | 1 |
| Yesil, S | 1 |
| Atabey, A | 1 |
| Ilgezdi, S | 1 |
| Gning, SB | 1 |
| Debonne, JM | 1 |
| Diagne-Guèye, NM | 1 |
| Ndiaye, B | 1 |
| Fall, F | 1 |
| Mbaye, PS | 1 |
| Yañez Díaz, S | 1 |
| Conde García, E | 1 |
| Mazo Polanco, E | 1 |
| Val Bernal, JF | 1 |
| Reilly, JT | 2 |
| Romanelli, M | 1 |
| Dini, V | 1 |
| Romanelli, P | 1 |
| Lanzkron, S | 1 |
| Strouse, JJ | 1 |
| Wilson, R | 1 |
| Beach, MC | 1 |
| Haywood, C | 1 |
| Park, H | 1 |
| Witkop, C | 1 |
| Bass, EB | 1 |
| Segal, JB | 1 |
| Nguyen, TV | 1 |
| Margolis, DJ | 1 |
| Estève, E | 1 |
| Roger, M | 1 |
| Nguyen, P | 1 |
| Kalis, B | 1 |
| Daoud, MS | 2 |
| Gibson, LE | 2 |
| Tomiyama, J | 1 |
| Yano, K | 1 |
| Uchino, S | 1 |
| Ito, T | 1 |
| Kudo, H | 1 |
| Irimajiri, J | 1 |
| Ohkubo, H | 1 |
| Kanazawa, A | 1 |
| Kawahara, Y | 1 |
| Best, PJ | 1 |
| Petitt, RM | 1 |
| Kennedy, BJ | 1 |
| Disla, E | 1 |
| D'Eamour, L | 1 |
| Cioriou, M | 1 |
| Weinlich, G | 2 |
| Schuler, G | 1 |
| Greil, R | 1 |
| Kofler, H | 1 |
| Fritsch, P | 2 |
| Liebschutz, S | 1 |
| Quéré, I | 1 |
| Lukasik, E | 1 |
| Dereure, O | 1 |
| Rondes, J | 1 |
| Janbon, C | 1 |
| Ruiz-Argüelles, GJ | 1 |
| Ruiz-Delgado, GJ | 1 |
| Ruiz-Reyes, G | 1 |
| Chernoff, SG | 1 |
| Suehiro, M | 1 |
| Kishimoto, S | 1 |
| Wakabayashi, T | 1 |
| Ikeuchi, A | 1 |
| Miyake, H | 1 |
| Takenaka, H | 1 |
| Okano, A | 1 |
| Hirai, H | 1 |
| Shimazaki, C | 1 |
| Yasuno, H | 1 |
| Kido, M | 1 |
| Tago, O | 1 |
| Fujiwara, H | 1 |
| Ito, M | 1 |
| Niwano, H | 1 |
| Kato, N | 1 |
| Kimura, K | 1 |
| Yasukawa, K | 1 |
| Yoshida, K | 1 |
| Mariéthoz, S | 1 |
| Pittet, B | 1 |
| Loutan, L | 1 |
| Humbert, J | 1 |
| Montandon, D | 1 |
| Varma, S | 2 |
| Lanigan, SW | 2 |
| Sirieix, ME | 1 |
| Debure, C | 1 |
| Baudot, N | 1 |
| Dubertret, L | 1 |
| Roux, ME | 1 |
| Morel, P | 1 |
| Frances, C | 1 |
| Loubeyres, S | 1 |
| Beylot, C | 1 |
| Lambert, D | 1 |
| Humbert, P | 1 |
| Gauthier, O | 1 |
| Dandurand, M | 1 |
| Guillot, B | 1 |
| Vaillant, L | 1 |
| Lorette, G | 1 |
| Bonnetblanc, JM | 1 |
| Lok, C | 1 |
| Denoeux, JP | 1 |
| Vélez, A | 1 |
| García-Aranda, JM | 1 |
| Moreno, JC | 1 |
| Stagno, F | 1 |
| Guglielmo, P | 1 |
| Consoli, U | 1 |
| Fiumara, P | 1 |
| Russo, M | 1 |
| Giustolisi, R | 1 |
| de Montalembert, M | 1 |
| Bégué, P | 1 |
| Bernaudin, F | 1 |
| Thuret, I | 1 |
| Micheau, M | 1 |
| Yasuda, N | 1 |
| Ohmori, S | 1 |
| Usui, T | 1 |
| Bader, U | 1 |
| Banyai, M | 1 |
| Böni, R | 1 |
| Burg, G | 1 |
| Hafner, J | 1 |
| Salmon-Ehr, V | 1 |
| Leborgne, G | 1 |
| Vilque, JP | 1 |
| Potron, G | 1 |
| Bernard, P | 1 |
| Flores, F | 1 |
| Eaglstein, WA | 1 |
| Kirby, B | 2 |
| Rogers, S | 1 |
| Pittelkow, M | 1 |
| Murphy, J | 1 |
| Morley, SM | 1 |
| Loukopoulos, D | 1 |
| Voskaridou, E | 1 |
| Kalotychou, V | 1 |
| Schina, M | 1 |
| Loutradi, A | 1 |
| Theodoropoulos, I | 1 |
| Abhyankar, D | 1 |
| Shende, C | 1 |
| Saikia, T | 1 |
| Advani, SH | 1 |
| Poros, A | 1 |
| Nádasdy, K | 1 |
| Chaine, B | 1 |
| Neonato, MG | 1 |
| Rain, JD | 1 |
| Young, HS | 1 |
| Stewart, EJ | 1 |
| Kersgard, C | 1 |
| Osswald, MB | 1 |
| Olesen, LH | 1 |
| Pedersen, BB | 1 |
| Kawabata, H | 1 |
| Kamada, T | 1 |
| Takatsuka, Y | 1 |
| Takeuchi, S | 1 |
| Suzuki, S | 1 |
| Makino, T | 1 |
| Utsunomiya, A | 1 |
| Lammintausta, K | 1 |
| Mäkelä, L | 1 |
| Remes, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Substudy of the CADRE Study: Determination of Clinical Markers in Patients With Extreme Sickle Cell Disease Phenotype[NCT03352986] | 300 participants (Anticipated) | Observational | 2017-05-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for hydroxyurea and Leg Ulcer
| Article | Year |
|---|---|
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Hydroxyurea: a reappraisal of its cutaneous side effects and their management.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Hyperpigmentation; Leg Ulcer; Skin; Skin Neoplasms | 2021 |
Critical Reviews: How we treat sickle cell patients with leg ulcers.
Topics: Anemia, Sickle Cell; Drug Therapy, Combination; Erythropoietin; Humans; Hydroxyurea; Leg Ulcer; Recu | 2016 |
Vasculitic and autoimmune wounds.
Topics: Anemia, Sickle Cell; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antiphospholipid Sy | 2017 |
Pulmonary hypertension and nitric oxide depletion in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Animals; Child; Clinical Trials as Topic; Disease Models, Animal; Echoca | 2010 |
[Medications. A rare cause for leg ulcers].
Topics: Aged; Diagnosis, Differential; Drug Hypersensitivity; Female; Humans; Hydroxyurea; Leg Ulcer; Long-T | 2011 |
Leg ulcers in sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Bandages; Blood Transfusion; Carnitine; Debridement; Drug | 2004 |
Leg ulcers in elderly on hydroxyurea: a single center experience in Ph- myeloproliferative disorders and review of literature.
Topics: Age Factors; Aged; Aged, 80 and over; Female; Humans; Hydroxyurea; Leg Ulcer; Male; Myeloproliferati | 2006 |
Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobins; Humans; Hydroxyurea; | 2008 |
Hydroxyurea-induced leg ulceration in 14 patients.
Topics: Adult; Antineoplastic Agents; Female; Humans; Hydroxyurea; Leg Ulcer; Male; Middle Aged; Myeloprolif | 1998 |
Hydroxyurea-related leg ulcers in a patient with chronic myelogenous leukemia: a case report and review of the literature.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-ABL Posit | 1999 |
[Falciform anemia and Plasmodium falciparum malaria: a threat to flap survival?].
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Leg Ulcer; Malaria, Falciparum | 1999 |
Leg ulcers in patients with myeloproliferative disorders: disease- or treatment-related?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Hydroxyurea; Leg | 2000 |
1 trial available for hydroxyurea and Leg Ulcer
| Article | Year |
|---|---|
Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Topics: Acute Disease; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Erythr | 2000 |
82 other studies available for hydroxyurea and Leg Ulcer
| Article | Year |
|---|---|
Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Female; Fetal Hemoglobin; Humans; Hydroxyurea; Inci | 2022 |
Treatment of Hydroxyurea-Induced Ulcers With Timolol.
Topics: Humans; Hydroxyurea; Leg Ulcer; Timolol; Ulcer | 2023 |
Sickle cell disease induces resistance to cutaneous carcinogenesis.
Topics: Adult; Anemia, Sickle Cell; Carcinogenesis; Cross-Sectional Studies; Humans; Hydroxyurea; Leg Ulcer; | 2020 |
Chronic Myeloid Leukaemia with Sudden Bilateral Deafness and Leg Ulcer Associated with Hydroxyurea Therapy.
Topics: Antineoplastic Agents; Hearing Loss, Bilateral; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenou | 2021 |
Hydroxyurea-induced genital ulcers and erosions: Two case reports.
Topics: Aged, 80 and over; Humans; Hydroxyurea; Leg Ulcer; Male; Myeloproliferative Disorders; Polycythemia | 2021 |
A Violaceous, Photodistributed Cutaneous Eruption and Leg Ulcer in a Woman With Essential Thrombocytosis.
Topics: Aged; Biopsy, Needle; Dermatomyositis; Exanthema; Female; Follow-Up Studies; Humans; Hydroxyurea; Im | 2018 |
Leg ulcer induced by hydroxycarbamide in sickle cell disease: What is the therapeutic impact?
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Leg Ulcer; Male; Middle Aged; Treatme | 2019 |
Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Drug Resistance; Female; Fever; Follow-Up Studies; Humans; Hydroxyur | 2019 |
Hydroxyurea-induced leg ulceration in a patient with a homozygous MTHFR polymorphism misdiagnosed as pyoderma gangrenosum.
Topics: Aged; Antineoplastic Agents; Diagnostic Errors; Female; Humans; Hydroxyurea; Leg Ulcer; Methylenetet | 2014 |
Dermatomyositis-like eruption associated with hydroxyurea therapy: a premalignant condition?
Topics: Aged; Dermatomyositis; Diagnosis, Differential; Drug Eruptions; Drug Substitution; Erythema; Female; | 2014 |
In vitro and in vivo anti-angiogenic effects of hydroxyurea.
Topics: Anemia, Sickle Cell; Angiogenesis Inhibitors; Animals; Cell Movement; Cell Proliferation; Human Umbi | 2014 |
Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Chronic Disease; Female; Humans; Hydroxyurea; Leg Ulcer; Middle Aged; Skin | 2014 |
Severity of Brazilian sickle cell disease patients: severity scores and feasibility of the Bayesian network model use.
Topics: Adult; Age Factors; Aged; Anemia, Sickle Cell; Antisickling Agents; Bayes Theorem; Bilirubin; Brazil | 2015 |
RX of sickle cell leg ulcers.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Sickle Cell; Female; Humans; Hydroxyurea; Leg Ulcer; Male; M | 2016 |
[MALLEOLAR ULCERS ASSOCIATED TO HYDROXYUREA TREATMENT].
Topics: Aged; Ankle; Female; Humans; Hydroxyurea; Leg Ulcer; Male | 2016 |
Dermatitis, nonmelanoma skin cancer and leg ulcers.
Topics: Aged, 80 and over; Antineoplastic Agents; Dermatomyositis; Female; Humans; Hydroxyurea; Keratosis, A | 2016 |
Malleolar ulcers due to hidroxyurea treatment.
Topics: Aged; Ankle; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Leg Ulcer | 2017 |
Hydroxyurea-induced ulcers on the leg.
Topics: Aged; Antineoplastic Agents; Diagnosis, Differential; Follow-Up Studies; Humans; Hydroxyurea; Leg Ul | 2009 |
[Cutaneous side effects of hydroxyurea treatment for polycythemia vera].
Topics: Aged; Antisickling Agents; Carcinoma, Squamous Cell; Drug Eruptions; Female; Humans; Hydroxyurea; Le | 2009 |
[Multiple, painful, treatment-resistant leg ulcers associated with dermatomyositis-like lesions over the interphalangeal joints induced by hydroxyurea].
Topics: Aged; Dermatomyositis; Female; Hand Dermatoses; Humans; Hydroxyurea; Interferon alpha-2; Interferon- | 2009 |
[Leg ulcers in patient affected by polycythemia vera in treatment with hydroxycarbamide. Case report].
Topics: Aged; Female; Humans; Hydroxyurea; Leg Ulcer; Polycythemia Vera; Treatment Outcome | 2010 |
Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antisickling Agents; Bone and Bones; Female; Humans; Hydroxy | 2010 |
Clinical follow-up of hydroxyurea-treated adults with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Drug Evaluation; Female; Follow- | 2011 |
Recurrence of hydroxyurea-induced leg ulcer after discontinuation of treatment.
Topics: Aged, 80 and over; Biopsy; Humans; Hydroxyurea; Leg Ulcer; Male; Polycythemia Vera; Recurrence; Trea | 2011 |
[Hydroxyurea induced-leg ulcer in polycythemia vera].
Topics: Aged; Antineoplastic Agents; Female; Humans; Hydroxyurea; Leg Ulcer; Polycythemia Vera | 2011 |
Mimicry of hydroxyurea-induced leg ulcer by distal vena saphena parva insufficiency.
Topics: Aged, 80 and over; Diagnosis, Differential; Humans; Hydroxyurea; Leg; Leg Ulcer; Male; Saphenous Vei | 2012 |
Study of correlation of nitrite levels with malonaldehyde and the prognosis of patients with sickle cell disease on hydroxyurea, Ceará-Brazil.
Topics: Adult; Anemia, Sickle Cell; Blood Transfusion; Brazil; Cohort Studies; Female; Humans; Hydroxyurea; | 2011 |
A multidisciplinary team approach to hydroxyurea-associated chronic wound with squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chronic Disease; Debridement; Female; Humans; Hydro | 2012 |
Prognostic implications of leg ulcers from hydroxycarbamide therapy in patients with essential thrombocythaemia.
Topics: Adult; Aged; Aged, 80 and over; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Leg Ulcer; Male; Mid | 2012 |
Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates.
Topics: Acute Chest Syndrome; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Cohort Studies; F | 2012 |
Sickle cell disease and leg ulcers.
Topics: Anemia, Sickle Cell; Blood Transfusion; Compression Bandages; Debridement; Hemoglobins; Humans; Hydr | 2012 |
Healing of an MRSA-colonized, hydroxyurea-induced leg ulcer with honey.
Topics: Administration, Topical; Enzyme Inhibitors; Female; Honey; Humans; Hydroxyurea; Immunocompromised Ho | 2001 |
Leg ulcers and hydroxyurea: report of three cases with essential thrombocythemia.
Topics: Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Hydroxyurea; Leg Ulce | 2002 |
Leg ulcers associated with hydroxyurea therapy.
Topics: Aged; Female; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2003 |
[Ulcers on the legs and feet: a seldom recognised side effect of hydroxyurea].
Topics: Aged; Antineoplastic Agents; Foot Ulcer; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chro | 2003 |
Hydroxyurea-induced skin ulcerations in patients with chronic myeloproliferative disorders.
Topics: Aged; DNA; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Leg Ulcer; Male; Middle Aged; Myeloprolif | 2003 |
Reversible leg ulcer due to hydroxyurea in a case of chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-AB | 2003 |
[Painful symmetrical ankle ulcerations. A 73-year old patient with chronic myeloid leukemia].
Topics: Aged; Ankle; Antineoplastic Agents; Debridement; Female; Humans; Hydroxyurea; Leg Ulcer; Leukemia, M | 2004 |
Leg ulcer in a patient associated with hydroxyurea therapy.
Topics: Alginates; Antineoplastic Agents; Bandages; Biguanides; Debridement; Glucuronic Acid; Hexuronic Acid | 2006 |
Healing of leg ulcers with hydroxyurea in thalassaemia intermedia patients with associated endocrine complications.
Topics: Adult; beta-Thalassemia; Female; Humans; Hydroxyurea; Leg Ulcer; Male | 2004 |
Hydroxyurea induced perimalleolar ulcers.
Topics: Aged; Ankle; Antineoplastic Agents; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, | 2006 |
Secondary cutaneous effects of hydroxyurea: possible pathogenetic mechanisms.
Topics: Aged; Arm; Diagnosis, Differential; Drug Eruptions; Humans; Hydroxyurea; Leg Ulcer; Male; Nucleic Ac | 2006 |
Painful leg ulcers and a rash in a patient with polycythaemia rubra vera. Diagnosis: hydroxyurea-induced leg ulceration and dermatomyositis-like skin changes.
Topics: Antineoplastic Agents; Female; Humans; Hydroxyurea; Leg Ulcer; Middle Aged; Myeloproliferative Disor | 2006 |
[Appearance of leg ulcers associated with intake of anagrelide].
Topics: Adult; Fibrinolytic Agents; Humans; Hydroxyurea; Leg Ulcer; Male; Quinazolines; Thrombocytosis | 2007 |
Hydroxyurea associated leg ulcer succesfully treated with hyperbaric oxygen in a diabetic patient.
Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hydroxyurea; Hyperbaric Oxygenation; Leg | 2007 |
[Leg ulcer due to hydroxyurea. A case report].
Topics: Antineoplastic Agents; Female; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-A | 2006 |
[Hydroxiurea-induced leg ulcers].
Topics: Aged; Female; Humans; Hydroxyurea; Leg Ulcer; Nucleic Acid Synthesis Inhibitors | 2007 |
Implications of the consensus definition of clinical resistance and intolerance to hydroxyurea for clinical practice.
Topics: Disease Management; Drug Resistance; Humans; Hydroxyurea; Leg Ulcer; Platelet Count; Thrombocythemia | 2007 |
Practical approach to treating essential thrombocythaemia: case studies.
Topics: Adult; Aspirin; Disease Management; Female; Humans; Hydroxyurea; Interferon-alpha; Leg Ulcer; Male; | 2007 |
Hydroxyurea-induced leg ulcers treated with a protease-modulating matrix.
Topics: Aged; Aged, 80 and over; Animals; Bandages, Hydrocolloid; Cattle; Cellulose, Oxidized; Collagen; Fem | 2007 |
Hydroxyurea and lower leg ulcers.
Topics: Aged; Female; Humans; Hydroxyurea; Leg Ulcer; Male; Middle Aged; Polycythemia Vera; Primary Myelofib | 1993 |
[A case for diagnosis: ulceration of the skin caused by hydrea].
Topics: Aged; Female; Humans; Hydroxyurea; Leg Ulcer | 1996 |
Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea.
Topics: Aged; Biopsy; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chro | 1997 |
[Bilateral leg ulcers with pathologic evidence of small vessel vasculitis by skin biopsy during hydroxyurea therapy of chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Biopsy; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-A | 1997 |
Hydroxyurea-associated leg ulceration.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leg Ulcer | 1998 |
Hydroxyurea-associated leg ulceration.
Topics: Aged; Antineoplastic Agents; Humans; Hydroxyurea; Leg Ulcer; Male | 1998 |
Leg ulcers associated with long-term hydroxyurea therapy.
Topics: Aged; Antineoplastic Agents; Female; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, | 1998 |
[Hyperalgesic malleolar ulcer: recovery on the withdrawal of hydroxyurea].
Topics: Ankle; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Hyperalgesia; Hyperpigmentation; Leg Ulcer; M | 1998 |
Anagrelide-induced relapse of a hydroxyurea-induced leg ulcer in a patient with primary thrombocythemia.
Topics: Aged; Antineoplastic Agents; Female; Fibrinolytic Agents; Humans; Hydroxyurea; Leg Ulcer; Platelet A | 1998 |
Hydroxyurea dermopathy with a dermatomyositis-like eruption and a large leg ulcer.
Topics: Antineoplastic Agents; Drug Eruptions; Female; Hand Dermatoses; Humans; Hydroxyurea; Leg Ulcer; Leuk | 1998 |
Leg ulcer associated with hydroxyurea treatment in a patient with chronic myelogenous leukaemia: successful treatment with prostagladin E1 and pentoxifylline.
Topics: Alprostadil; Antineoplastic Agents; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, | 1998 |
Leg ulceration with associated thrombocytosis: healing of ulceration associated with treatment of the raised platelet count.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-ABL Posit | 1999 |
Dermatomyositis-like eruption and leg ulceration caused by hydroxyurea in a patient with psoriasis.
Topics: Aged; Aged, 80 and over; Dermatologic Agents; Dermatomyositis; Drug Eruptions; Female; Humans; Hydro | 1999 |
Leg ulcers and hydroxyurea: forty-one cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Eruptions; Female; Humans; Hydroxyurea; | 1999 |
Leg ulcers in patients treated with hydroxyurea for myeloproliferative disorders: what is the trigger?
Topics: Drug Eruptions; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nu | 1999 |
Hydroxyurea-induced leg ulcers: is macroerythrocytosis a pathogenic factor?
Topics: Animals; Dogs; Female; Humans; Hydroxyurea; Leg Ulcer; Middle Aged; Nucleic Acid Synthesis Inhibitor | 1999 |
Successful healing of hydroxyurea-related leg ulcers with topical granulocyte-macrophage colony-stimulating factor.
Topics: Administration, Topical; Adult; Aged; Antineoplastic Agents; Female; Granulocyte-Macrophage Colony-S | 1999 |
Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Cohort Studies | 1999 |
Hydroxyurea-induced gangrene of the toes in a patient with chronic myelogenous leukemia.
Topics: Adult; Amputation, Surgical; Antineoplastic Agents; Female; Gangrene; Humans; Hydroxyurea; Interfero | 2000 |
[Secondary cutaneous effects of hydroxyurea: prospective study of 26 patients from a dermatologic consultation].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Humans; Hydroxyurea; Leg Ulcer; Myeloproliferative | 2000 |
Hydroxyurea-induced leg ulcers treated with Apligraf.
Topics: Aged; Antineoplastic Agents; Collagen; Female; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous | 2000 |
Dermatomyositis-like eruption and leg ulceration caused by hydroxyurea in a patient with psoriasis.
Topics: Drug Eruptions; Humans; Hydroxyurea; Leg Ulcer; Psoriasis | 2000 |
Hydroxyurea-induced leg ulcers.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-ABL Posit | 2000 |
Hydroxyurea induced leg ulcers.
Topics: Adult; Antineoplastic Agents; Fatal Outcome; Female; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelo | 2000 |
Leg ulcer in hydroxyurea-treated patients.
Topics: Aged; Antineoplastic Agents; Female; Humans; Hydroxyurea; Leg Ulcer; Male; Middle Aged; Myeloprolife | 2000 |
Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease.
Topics: Adult; Age Factors; Anemia, Sickle Cell; Antisickling Agents; Female; Humans; Hydroxyurea; Leg Ulcer | 2001 |
[Hydroxyurea--is it a harmless drug in Vaquez disease?]].
Topics: Aged; Alopecia; Combined Modality Therapy; Cystitis; Erectile Dysfunction; Female; Fever; Follow-Up | 2001 |
Aggressive, extensive, vasculitic leg ulceration associated with hydroxyurea therapy and a fatal outcome.
Topics: Aged; Cyclophosphamide; Fatal Outcome; Female; Foot Ulcer; Glucocorticoids; Humans; Hydroxyurea; Imm | 2001 |
Hydroxyurea and sickle cell leg ulcers.
Topics: Anemia, Sickle Cell; Female; Humans; Hydroxyurea; Leg Ulcer; Middle Aged | 2001 |
[Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders].
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Female; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelo | 2001 |
Successful treatment for leg ulcers due to hydroxyurea in a patient with chronic myelogenous leukaemia.
Topics: Antineoplastic Agents; Debridement; Drug Combinations; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Mye | 2002 |
[A hydroxyurea-induced leg ulceration].
Topics: Antineoplastic Agents; Drug Eruptions; Female; Humans; Hydroxyurea; Leg Ulcer; Middle Aged; Polycyth | 2001 |